UPDATE : Thursday, May 23, 2019
상단여백
‘Risk-sharing agreements back up economic feasibility review’
An expert said expanding risk-sharing agreements (RSA) and introducing a po...
by Kim Yun-mi  |  2019-05-22 14:46
라인
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too?
Japan’s Health Ministry warned that Eli Lilly’s breast cancer therapy Verze...
by Kim Yun-mi  |  2019-05-21 14:19
라인
Low-income, single women more vulnerable to osteoporosis
Women who are living by herself, earning low incomes, and having poor knowl...
by Kim Yun-mi  |  2019-05-20 15:40
라인
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride
The Korean Diabetes Association (KDA)’s revised guideline for diabetes trea...
by Kim Yun-mi  |  2019-05-15 15:30
라인
Keytruda wins nod as adjuvant therapy after melanoma surgery
The Ministry of Food and Drug Safety has approved PD-1 inhibitor immunother...
by Kim Yun-mi  |  2019-05-15 14:14
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon
With Roche’s HER2-positive breast cancer drug Herceptin (trastuzumab) facin...
by Kim Yun-mi  |  2019-05-13 14:23
라인
Xeljianz is easier to use than biologic therapies -- is it safer, however?
Pfizer’s Xeljianz (tofacitinib), an oral Janus kinase (JAK) inhibitor to tr...
by Kim Yun-mi  |  2019-05-10 15:34
라인
[Exclusive] MSD Korea playing tricks to reduce daycare cost
Korea Biomedical Review ran an exclusive story on an executive at MSD Korea...
by Kim Yun-mi  |  2019-05-09 11:20
라인
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too
Immunotherapies have become so effective and popular that some cancer patie...
by Kim Yun-mi  |  2019-05-07 14:30
라인
Leading hepatitis C drug wins FDA nod for adolescents
AbbVie’s hepatitis C treatment Mavyret (glecaprevir/pibrentasvir), which wo...
by Kim Yun-mi  |  2019-05-03 15:51
라인
New head of HUMC to put focus on research
Hanyang University Medical Center will enhance its specialty as a universit...
by Kim Yun-mi  |  2019-05-02 16:57
라인
‘MSD Korea’s monitoring program might be privacy breach’
MSD Korea’s “Self-Assurance” program, recording conversations of doctors at...
by Kim Yun-mi  |  2019-05-02 11:00
라인
Drugmakers brace for vaccine shortage amid surging hepatitis A cases
Pharmaceutical companies are closely monitoring the supply of hepatitis A v...
by Kim Yun-mi  |  2019-04-30 13:13
라인
Breast cancer society to focus on patients’ quality of life
Korean Breast Cancer Society said the nation has achieved one of the world’...
by Kim Yun-mi  |  2019-04-26 14:22
라인
‘PD-L1 expression poor marker for bladder cancer’s immunotherapy’
More than a year has passed since Tecentriq (atezolizumab), new immunothera...
by Kim Yun-mi  |  2019-04-25 11:52
라인
[News Focus] Cholesterol-reducing PCSK9 inhibitors get popular -- cost-effective, too?
PCSK9 inhibitors have become more popular for patients with a high-risk car...
by Kim Yun-mi  |  2019-04-24 12:35
라인
How to improve treatment guidelines for dyslipidemia?
Dyslipidemia specialists have called for the Korean treatment guidelines on...
by Kim Yun-mi  |  2019-04-22 14:50
라인
‘No need to reduce number of drugs for triple-drug therapy to treat HIV’
In the past, HIV and AIDS were known as deadly diseases that could take awa...
by Kim Yun-mi  |  2019-04-18 15:20
라인
Novartis’ new macular degeneration drug has to compete against colon cancer drug Avastin. Why?
Novartis’ new treatment for macular degeneration might have to fight agains...
by Kim Yun-mi  |  2019-04-18 14:42
라인
Immunotherapies’ liver cancer-treating effects confirmed in real-world studies
Researchers unveiled the world’s first real-world data to show how immunoth...
by Kim Yun-mi  |  2019-04-15 14:29
여백
여백
여백
Back to Top